{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rial NS"],"funding":["NCI NIH HHS"],"pagination":["507-17"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3587976"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(4)"],"pubmed_abstract":["To reduce the morbidity and mortality from colorectal cancer (CRC), current clinical practice focuses on screening for early detection and polypectomy as a form of secondary prevention, complemented with surgical interventions when appropriate. No pharmaceutical agent is currently approved for use in clinical practice for the management of patients at risk for CRC. This article will review earlier attempts to develop pharmaceuticals for use in managing patients with a sporadic or genetic risk of CRC. It will also discuss therapeutic end points under evaluation in current efforts to develop drugs for treating CRC risk factors."],"journal":["Expert review of gastroenterology & hepatology"],"pubmed_title":["Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer."],"pmcid":["PMC3587976"],"funding_grant_id":["CA072008","CA123065","CA088078","CN075019","P50 CA095060","R01 CA088078","CA059024","CA095060","R01 CA123065","P01 CA072008","CA047396","P30 CA062203","N01 CN075019","R01 CA059024"],"pubmed_authors":["Zell JA","Rial NS","Cohen AM","Gerner EW"],"additional_accession":[]},"is_claimable":false,"name":"Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer.","description":"To reduce the morbidity and mortality from colorectal cancer (CRC), current clinical practice focuses on screening for early detection and polypectomy as a form of secondary prevention, complemented with surgical interventions when appropriate. No pharmaceutical agent is currently approved for use in clinical practice for the management of patients at risk for CRC. This article will review earlier attempts to develop pharmaceuticals for use in managing patients with a sporadic or genetic risk of CRC. It will also discuss therapeutic end points under evaluation in current efforts to develop drugs for treating CRC risk factors.","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 Aug","modification":"2020-11-19T14:14:01Z","creation":"2019-03-27T01:05:35Z"},"accession":"S-EPMC3587976","cross_references":{"pubmed":["22928902"],"doi":["10.1586/egh.12.23"]}}